The Drug Market for Sexual Disorders is Worth Around US$3.8 Billion, and is Expected to Increase by 74% to US$6.6 Billion by 2012

Dublin (PRWEB) January 25, 2006

Research and Markets ( has announced the addition of Spectra Intelligence report: The global market for Sexual Disorders, 2005-2012:. Crossing New Frontiers in Sexual Chemistry to their offering


sexual disorder pharmacotherapy is dominated by drugs indicated for erectile dysfunction which controls about 78% of the total market for sexual dysfunction estimated U.S. $ 3 billion. Significant market opportunities are evident for the expansion of androgenic therapies to treat sexual disorders in new population groups, as in women with hypoactive sexual desire disorder and the male andropause. In addition, new drugs are under way to redefine the landscape of sexual medicine by providing new treatments for premature ejaculation and specific desire arousal disorders.

Emerging drug treatments

targeting unmet needs of women with sexual dysfunction are poised to revolutionize the market for sexual dysfunction, and Spectra predicts that female sexual dysfunction sector may outperform those therapies indicated for male sexual problems in d a decade of availability. However, as a treatment area relatively young and controversial, new drugs for sexual dysfunction are subject to intense regulatory scrutiny and navigate through the approval process for drugs is a particular challenge for new indications of problems sex, which is evident from recent setbacks marketing authorization for Proctor & Gamble Intrinsa for women of hypoactive sexual desire disorder and Dapoxetine Johnson & Johnson / Alza ‘s for premature ejaculation. However, in this report, the global market for sexual dysfunction, 2005-2012: Across New Frontiers in Sexual Medicine, the reader will be presented to a specialty pharmaceutical market is the transition to a dynamic, high-value therapeutic area estimated at more than U.S. $ 6.6 billion in 2012.

The report provides a detailed analysis of the therapy area of ​​sexual dysfunction to include ideas for extending products and reformulation, sales forecasts for 2012, and the impact of pipeline drugs at a stage advanced on the market. An overview of R & D programs in the field is highlighted showing products from preclinical to phase prior authorization for marketing development, with promising agents further discussed business development opportunities and drugs. Forecast therapy area and market data for illustration and analysis is also presented to provide an overview of potential high-performance products. Forecast therapy area in 2020 also allows the reader to make key assumptions about markets and future prospects, and use the data for predictive modeling of exclusive market.

The objectives of this report is to provide a thorough analysis of global market disorder sex therapy. Included in this study are the analysis of key therapeutic areas, R & D programs and innovative companies and products. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and analytical discourse, which aims to stimulate growth and create new opportunities.

For more information visit

Laura Wood

Senior Manager

Research and Markets

Fax: +353 1 4100 980

More Premature Ejaculation Press Releases

This entry was posted in Premature Ejaculation and tagged , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

Notify me of followup comments via e-mail. You can also subscribe without commenting.